Evidence map›Paper›PMID 39391592›Full record

ArticleGastroenterology report2024

Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer.

Fu-Rong Kou, Jian Li, Zheng-Hang Wang, Ting Xu, Juan-Juan Qian, En-Li Zhang, Li-Jun Zhang, Lin Shen, Xi-Cheng Wang

Abstract read
In one paragraph

Article in Gastroenterology report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Impact of MMR status on preoperative CT-based lymph node overstaging in right-sided colon cancer: a retrospective analysis.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  2. Identification and Characterization of a NovelInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fu-Rong KouKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
Jian LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
Zheng-Hang WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
Ting XuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
Juan-Juan QianDepartment of Medicine, Genecast Biotechnology Co., Ltd., Wuxi, Jiangsu, P. R. China.
En-Li ZhangDepartment of Medicine, Genecast Biotechnology Co., Ltd., Wuxi, Jiangsu, P. R. China.
Li-Jun ZhangDepartment of Medicine, Genecast Biotechnology Co., Ltd., Wuxi, Jiangsu, P. R. China.
Lin ShenKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.ORCID https://orcid.org/0000-0002-8798-4756
Xi-Cheng WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prevalence of gene fusion is extremely low in unselected patients with colorectal cancer (CRC). Published data on gene fusions are limited by relatively small sample sizes, with a primary focus on Western populations. This study aimed to analyse actionable gene fusions in a large consecutive Chinese CRC population. Methods: This study included 5,534 consecutive CRC patients from the Genecast database. Genomic profiling was performed using a panel of 769 cancer-related genes. Data for 34 CRC patients with actionable gene fusions were also collected from cBioPortal and ChimerSeq. Results: Among 5,534 CRC patients, 54 (0.98%) had actionable gene fusions, with Conclusions: Approximately 1% of the unselected Chinese CRC population carries actionable gene fusions, mostly involving

Indexed as

actionable gene fusionsChinese populationcolorectal cancer

Identifiers

PMID39391592
PMCPMC11464618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.